- Home
- CRT vs MNOV Comparison
CRT vs MNOV Comparison
Compare CRT & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | MNOV |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.2M | 69.4M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | CRT | MNOV |
|---|---|---|
| Price | $10.81 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 17.9K | ★ 22.2K |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $7.07 | $1.17 |
| 52 Week High | $11.10 | $1.96 |
Technical Indicators
Market Signals| Indicator | CRT | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 37.24 |
| Support Level | $10.15 | $1.20 |
| Resistance Level | $11.08 | $1.32 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 74.67 | 20.00 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.